Leading the charge to a pain free tomorrow.

4E Therapeutics is a neuroscience company based in Austin, Texas focused on developing next generation treatments for pain. With a history of commercial success and scientific expertise, 4E Therapeutics has entered clinical development for a cutting edge therapy for chronic neuropathic pain and is also at the forefront of discovering and developing compounds to treat migraine and acute pain.

Leadership Team

Meet Our Team

The company, founded by a world-class team of experts, is dedicated to improving the lives of those living in pain by developing innovative, non-addictive pain medications that target the underlying neurological mechanisms that cause pain.

Chief Executive Officer

Craig Benson

Since February, 2020, T. Craig Benson has served as CEO of 4E Therapeutics, Inc., an early stage virtual therapeutic development company. In addition, Benson has been Founder and Executive Chairman of the Board of Directors of Beyond Batten Disease Foundation (BBDF) since October 2008. BBDF is engaged in therapeutic development and patient advocacy for the juvenile form of Batten Disease. Its lead candidate, BBDF-101, has recently been approved by the FDA to commence clinical trials and has been licensed to a publicly traded pharmaceutical company for further development. From 2002-2014, Mr. Benson was CEO and President of Rules-Based Medicine, Inc. (later MyriadRBM, Inc.), a life science pharma service/diagnostic company, after directing its spin-off from Luminex Corporation (NASDAQ:LMNX). The business was acquired by Myriad Genetics (NASDAQ:MYGN) in 2011.   During 2000-2004, he also served as Chairman of the Board for Equity Resource Partners, LLC, a private investment company.  From 1987- 2000, Benson was employed by Service Corporation International (NYSE: SCI).  During his tenure with SCI, he held various senior executive management positions, which included domestic and international merger and acquisition responsibilities, Vice-President of Marketing and Corporate Alliances, as well as President of SCI International, Ltd., SCI’s International holding company with over $2 billion in overseas operations. From 1990 to 1994, Benson served as President of Investment Capital Corporation, the private equity arm of SCI, which held over $350 million in assets. From 1984 to 1987, he held management positions with Pulaski Investment Corporation, a bank holding company engaged in commercial and mortgage finance activities.

Benson has been General Partner of CTX Capital Partners, LLC since 2019. CTX is engaged in developing and managing attainable housing communities as well as other real estate investments. Mr. Benson has served as General Partner at Caddo Minerals, Inc. since 2013, which is a private energy investment company. Mr. Benson has served on the Board of Directors of four publicly held companies and is a member of Young Presidents Organization (YPO). Also, he is a member of the International Advisory Board of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, Texas. He received a BBA degree from Southern Methodist University in 1984.

Co-Founder, President & Chairman

Joe Price

Joe Price co-founded and is currently the President and Chairman of 4E Therapeutics. Joe has also co-founded and led several other companies, including CampusOptics, Inc. and AcademicWorks, Inc., which was acquired by Blackbaud, Inc. (NASDAQ: BLKB) in 2017.  Joe is an attorney who previously practiced law at Baker Botts L.L.P., where he represented clients in both business and patent litigation, and served as the law clerk to the Honorable Leonard Davis of the United States District Court for the Eastern District of Texas, who, at the time, had one of the largest patent dockets in the Federal Judiciary. Joe holds a BA in Government from the University of Texas at Austin, a JD, magna cum laude, from Baylor Law School, where he served as the Editor-in-Chief of the Baylor Law Review, and an MBA in entrepreneurship from the Acton School of Business.
Co-Founder

Ted Price

Theodore (Ted) Price is Ashbel Smith Professor in the Department of Neuroscience in the School of Behavioral and Brain Sciences at University of Texas (UT) at Dallas. He is also the Director of the Center for Advanced Pain Studies at UT Dallas. He did his PhD work with Chris Flores and Ken Hargreaves at UT Health San Antonio and a postdoctoral fellowship at McGill University with Fernando Cervero. He started his independent laboratory in 2007 at University of Arizona School of Medicine and moved to UT Dallas in 2014. His lab is interested in molecular mechanisms driving the transition to chronic pain with a focus on drug development for chronic pain disease modification and on peripheral and central mechanisms of neuronal plasticity in response to injury. He has won numerous awards including the Patrick D. Wall Young Investigator Award from IASP. He is editor in chief of Neurobiology of Pain and on the editorial board of Journal of Neuroscience and PAIN. Ted has published more than 150 peer reviewed studies, has been continuously funded by NIH for more than 10 years, and is a former member of the Neurobiology of Pain and Itch Study Section for NIH. He is a co-founder of several companies, including 4E Therapeutics, CerSci Therapeutics, which was acquired by Acadia Pharma in 2020, and Doloromics which is alumni company of the Illumina Accelerator program.

A major part of Ted’s work has focused on signaling mechanisms that cause nociceptors to become sensitized in chronic pain states. His work on MNK and eiF4E phosphorylation demonstrates this pathway is a central node in the signaling events that cause chronic pain. This scientific foundation formed the impetus to start 4E Therapeutics. Ted’s ongoing work at 4E Therapeutics has focused on developing this target pathway, building the neurobiology arm of 4E’s discovery platform and developing a clinical bridge program that leverages advances in human molecular neuroscience to demonstrate the efficacy of MNK inhibitors in reducing human nociceptor excitability.

Vice President of Drug Development

James Sahn

James Sahn is the Vice President of Drug Development at 4E Therapeutics. He received his Ph.D. from North Carolina State University (Daniel Comins) and conducted postdoctoral studies at The University of Texas (UT) at Austin (Stephen Martin). Sahn has 20 years of experience in synthetic-organic chemistry with a focus on the design and synthesis of bioactive small molecules with medicinal properties. His research interests lie broadly in the areas of medicinal chemistry, pharmacology, pharmacokinetics, and new treatment modalities for neurodegenerative- and neurological disorders. Toward this end, he has studied the sigma 2 receptor (σ2R) for its involvement in a wide range of neurological conditions.

Sahn and collaborators have synthesized hundreds of σ2R modulators across multiple compound classes, leading to the discovery of pharmacological tools with neuroprotective- and analgesic properties. These efforts led to the cloning and identification of σ2R as transmembrane protein 97 (TMEM97), enabling previously unavailable biological investigations that have further enhanced the understanding of this potential drug target. Sahn has published 20 peer review articles, is a co-inventor on nine patent applications, and is a co-founder of NuvoNuro, a UT Austin spinout.

Grants Accountant & Administrator

Suzanne MacGillivray

Suzanne has over 20 years experience in business and non-profit accounting and operations management. As the Accounting Manager at AcademicWorks, she managed Accounting, Human Resources, and Operations. Prior to working with AcademicWorks, she was the Purchasing, Payables & Receivables Manager at SafePlace. She managed several aspects of the merger of SafePlace and the Austin Children’s Shelter, bringing together Finance and Development processes for 2 large non-profits, training and supervising staff, and happily answering many, many questions. Suzanne holds a Bachelor of Science from the University of Mary Hardin-Baylor.